Stapokibart

司普奇拜单抗

Report date: 2026/05/13 20:02:10

Base Information

Drug NameStapokibart
Drug Alias NameScipibazumabStapokibatrt康悦达KangyuedaCM-310
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Prurigo NodularisSolid tumours +[14] 
Global Approved IndicationsDermatitis, Atopic
Approved Indications in ChinaDermatitis, Atopic
Original Approved Country/TerritoryMainland China
Original Approved Date2024/09/10
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesKeymed Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdChengdu Kangnuoxing Biopharma IncKeymed Biosciences Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Prurigo NodularisSolid tumours +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank